Special purpose acquisition companies (SPACs) continue to pique investor interest as an attractive mechanism through which a private company can raise growth capital and become a publicly traded entity. As of June 2021, 330 SPACs have raised nearly $105 billion, a significant jump compared to previous years, according to SPAC Research. Further, SPACs and de-SPAC transactions are on the radar of the Securities and Exchange Commission which continues to consider investor protection measures.
Please join Bass, Berry & Sims and J.P. Morgan on September 14 at 11:00 a.m. Central for a complimentary webinar exploring the continued interest in the use of SPACs and lessons learned from the trenches. Bass, Berry & Sims Private Equity Chair and Healthcare Private Equity Team Co-Chair, Ryan Thomas, will lead a discussion with panelists Jay Knight, Member and Capital Markets Team Chair at Bass, Berry & Sims and Eric Rabinowitz, Managing Director and Healthcare M&A Co-Head at J.P. Morgan who will share their first-hand experiences. Speakers will cover the following topics:
- History of the SPAC and de-SPAC structure.
- Advantages and disadvantages compared to a traditional IPO or M&A transaction.
- Rise in popularity of SPACs in healthcare sector.
- Potential private investment in public equity (PIPE) financing considerations.
- De-SPAC transaction lessons learned.